↓ Skip to main content

Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis

Overview of attention for article published in Clinical Pharmacokinetics, June 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (69th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
8 X users

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
39 Mendeley
Title
Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis
Published in
Clinical Pharmacokinetics, June 2018
DOI 10.1007/s40262-018-0678-x
Pubmed ID
Authors

Jürgen B. Bulitta, Yuanyuan Jiao, Stefanie K. Drescher, Antonio Oliver, Arnold Louie, Bartolome Moya, Xun Tao, Mathias Wittau, Brian T. Tsuji, Alexandre P. Zavascki, Beom Soo Shin, George L. Drusano, Fritz Sörgel, Cornelia B. Landersdorfer

Abstract

The pharmacokinetics (PK) of β-lactam antibiotics in cystic fibrosis (CF) patients has been compared with that in healthy volunteers for over four decades; however, no quantitative models exist that explain the PK differences between CF patients and healthy volunteers in older and newer studies. Our aims were to critically evaluate these studies and explain the PK differences between CF patients and healthy volunteers. We reviewed all 16 studies that compared the PK of β-lactams between CF patients and healthy volunteers within the same study. Analysis of covariance (ANCOVA) models were developed. In four early studies that compared adolescent, lean CF patients with adult healthy volunteers, clearance (CL) in CF divided by that in healthy volunteers was 1.72 ± 0.90 (average ± standard deviation); in four additional studies comparing age-matched (primarily adult) CF patients with healthy volunteers, this ratio was 1.46 ± 0.16. The CL ratio was 1.15 ± 0.11 in all eight studies that compared CF patients and healthy volunteers who were matched in age, body size and body composition, or that employed allometric scaling by lean body mass (LBM). Volume of distribution was similar between subject groups after scaling by body size. For highly protein-bound β-lactams, the unbound fraction was up to 2.07-fold higher in older studies that compared presumably sicker CF patients with healthy volunteers. These protein-binding differences explained over half of the variance for the CL ratio (p < 0.0001, ANCOVA). Body size, body composition and lower protein binding in presumably sicker CF patients explained the PK alterations in this population. Dosing CF patients according to LBM seems suitable to achieve antibiotic target exposures.

X Demographics

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 39 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 10%
Student > Bachelor 4 10%
Researcher 4 10%
Professor 2 5%
Other 2 5%
Other 6 15%
Unknown 17 44%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 6 15%
Medicine and Dentistry 3 8%
Biochemistry, Genetics and Molecular Biology 2 5%
Immunology and Microbiology 2 5%
Chemistry 2 5%
Other 8 21%
Unknown 16 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 August 2018.
All research outputs
#5,828,064
of 23,567,572 outputs
Outputs from Clinical Pharmacokinetics
#454
of 1,519 outputs
Outputs of similar age
#98,252
of 329,720 outputs
Outputs of similar age from Clinical Pharmacokinetics
#9
of 18 outputs
Altmetric has tracked 23,567,572 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,519 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,720 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.